Article Information
History
- October 21, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Quazim A. Alayo, MD MSc MMSc1,2,
- Aava Khatiwada, MD3,
- Anish Patel, DO4,
- Maria Zulfiqar, MD5,
- Anas Gremida, MD1,
- Alexandra Gutierrez, MD MPH1,
- Richard P. Rood, MD1,
- Matthew A. Ciorba, MD1,
- George Christophi, MD PhD1,6 and
- Parakkal Deepak, MBBS MS1,*
- 1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
- 2Department of Internal Medicine, St. Luke’s Hospital, Chesterfield, MO, USA
- 3Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA
- 4Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA
- 5Department of Radiology, Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, MO, USA
- 6Department of Medicine, University of Central Florida, Orlando, FL, USA
- ↵*Corresponding author:
Parakkal Deepak, MBBS, MS, Assistant Professor of Medicine, John T. Milliken Department of Medicine, Division of Gastroenterology, Washington University in St. Louis School of Medicine, 660 S. Euclid Avenue, Campus Box 8124, St. Louis, MO 63110, USA., Phone: 314-273-1947., Fax: 314-747-5871, E-mail: deepak.parakkal{at}wustl.edu
Author Contributions: PD, AP, AK, and QAA conceived and designed the study. AK, QAA, AP contributed to the acquisition of the data. QAA and PD analyzed data and drafted the initial manuscript. Interpretation of results and critical revisions was by RPR, MAC, AG, AG, MZ and GC. All authors approved the final version of the manuscript.
Posted October 21, 2020.
Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
